Tovorilimab
Rectal Cancer, Adenocarcinoma
Beijing Friendship HospitalPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Rectal Cancer, Adenocarcinoma cohort.
Same molecule, other indications
Tovorilimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →